

# 'Stem cell Trial of recovery EnhanceMent after Stroke 2' (STEMS2): pilot randomised placebo-controlled trial of granulocyte-colony stimulating factor in mobilising bone marrow stem cells in sub-acute stroke

<b>Submission date</b> 22/05/2006	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 07/11/2006	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 16/08/2012	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

## Plain English Summary

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Prof Philip Bath

### Contact details

Stroke Trials Unit  
Queens Medical Centre  
University of Nottingham  
Nottingham  
United Kingdom  
NG7 2UH

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

## Secondary identifying numbers

Version 1.0

# Study information

## Scientific Title

## Acronym

STEMS2

## Study hypothesis

We hypothesise that Granulocyte Colony Stimulating Factor (G-CSF) mobilised Peripheral Blood Stem Cells (PBSCs) in patients with recent ischaemic stroke will migrate to the brain and promote recovery.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Ethics approval received from the Nottingham LREC 1 on the 22nd May 2007 (ref: 07/Q2403/27).

## Study design

Randomised placebo controlled double blind and endpoint blinded trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Hospital

## Study type(s)

Treatment

## Participant information sheet

## Condition

Ischaemic stroke

## Interventions

Subcutaneous human recombinant G-CSF (Filgrastim 1 x 10<sup>6</sup> u/kg) versus saline started three to 30 days after stroke onset and given for five days.

## Intervention Type

Drug

## Phase

Not Specified

**Drug/device/biological/vaccine name(s)**

Filgrastim

**Primary outcome measure**

Number of patients having a serious adverse event by day 90.

**Secondary outcome measures**

1. Laboratory measures including CD34+ count
2. Clinical efficacy:
  - 2.1. Impairment
  - 2.2. Dependency disability
  - 2.3. Functional independence
  - 2.4. Quality of life
3. Length of stay in hospital, discharge disposition
4. Neuroimaging: including lesion size
5. Feasibility

**Overall study start date**

02/07/2007

**Overall study end date**

31/03/2010

## **Eligibility**

**Participant inclusion criteria**

1. Clinical stroke (lacunar or cortical)
2. Ischaemic or haemorrhagic type on neuro-imaging three to 30 days post-onset
3. Arm and/or leg weakness (Scandinavian Stroke Scale [SSS] arm and/or leg motor power less than six)

**Participant type(s)**

Patient

**Age group**

Not Specified

**Sex**

Not Specified

**Target number of participants**

60

**Participant exclusion criteria**

Prior to 09/09/09:

1. Pre-morbid dependency, modified Rankin Scale (mRS) more than three
2. Primary intracerebral haemorrhage
3. Dementia

4. Coma (SSS consciousness less than four)
5. Malignancy
6. Sickle cell disease
7. Pregnancy (see data sheet/British National Formulary [BNF] for other G-CSF contra-indications)
8. Known contra-indication to Magnetic Resonance Imaging (MRI)

Amended 09/09/09:

1. Pre-morbid dependency, modified Rankin Scale (mRS) more than three
2. Dementia
3. Coma (SSS consciousness less than four)
4. Malignancy
5. Sickle cell disease
6. Pregnancy (see data sheet/British National Formulary [BNF] for other G-CSF contra-indications)
7. Known contra-indication to Magnetic Resonance Imaging (MRI)

**Recruitment start date**

02/07/2007

**Recruitment end date**

31/03/2010

## Locations

**Countries of recruitment**

England

United Kingdom

**Study participating centre**

**Stroke Trials Unit**

Nottingham

United Kingdom

NG7 2UH

## Sponsor information

**Organisation**

University of Nottingham (UK)

**Sponsor details**

Nottingham City Hospital Campus

Hucknall Road

Nottingham

England

United Kingdom  
NG5 1PB

**Sponsor type**  
University/education

**Website**  
<http://www.nottingham.ac.uk/>

**ROR**  
<https://ror.org/01ee9ar58>

## Funder(s)

**Funder type**  
Research council

**Funder Name**  
Medical Research Council (MRC) (UK) - Grant application G0501997

## Results and Publications

**Publication and dissemination plan**  
Not provided at time of registration

**Intention to publish date**

**Individual participant data (IPD) sharing plan**

**IPD sharing plan summary**  
Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/02/2012		Yes	No